# Pharming Group N.V. share price today (Pharming Group N.V., PHAR)

> Pharming Group N.V.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PHAR · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/phar

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $12.46 (−19.2% in a year)
- P/E: 43.8×, over 4.6 years
- Revenue (Jun 2026): $90.2 M (−3.2% on a year ago)
- Profit (Jun 2026): $1.6 M (−65.1% on a year ago)
- Operating margin: 1.5% (−10.1 points on a year ago)
- ROE: 1%, FY25
- ROIC: 15.8%, against a 4.5% cost of capital: +11.3 points
- Profit that came in as cash: 354%, last 3 years

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Pharming Group N.V. share price today? Pharming Group N.V.'s share price was $12.46 at the close on 4 November 2026. It has been falling for 5 weeks. That is 9.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $9 and $20, and at that close it sat 28% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 5.9 years the share price moved −20% while the S&P 500 moved +99%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Pharming Group N.V. pay? Pharming Group N.V. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Pharming Group N.V. on? Pharming Group N.V. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Pharming Group N.V. profitable? Pharming Group N.V. earned $1.6 M of net profit in the Jun 2026 quarter, −65.1% on the same quarter a year earlier. Full-year FY25 profit was $2.9 M. Over 4 years profit has grown −35.0% a year on average. That is 1.8% of the quarter's revenue. The same quarter a year earlier earned $4.7 M. 6 of the last 12 reported quarters were loss-making. ## How much revenue does Pharming Group N.V. make, and is it growing? Pharming Group N.V. reported $90.2 M of revenue in the Jun 2026 quarter, −3.2% on the same quarter a year earlier. Over 4 years it has grown 17.3% a year on average. The last full year, FY25, came in at $376 M. The last four reported quarters add to $366 M. FY25 revenue was $376 M, +26.6% on the year before. Recent pace: the last four quarters grew +8.3% on average, against 17.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +7.8%, against +14.9% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Pharming Group N.V. keep? Pharming Group N.V.'s operating margin was 1.5% in the Jun 2026 quarter, 10.1 percentage points lower than the same quarter a year ago. Across 5 years it has been between −8.9% and 12.1%. The latest quarter is within that range. Why the margin moved: operating margin changed −10.1 percentage points on the year while gross margin changed −6.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Pharming Group N.V.'s profit turning into cash? Over the last 3 years, 354% of Pharming Group N.V.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $54.7 M of operating cash against $2.9 M of profit. After $749 K of spending on assets, $54.0 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Pharming Group N.V.'s cash go? Pharming Group N.V. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.0 M on assets over the last 3 years. Averaged over those years that is 0.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $3.0 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Pharming Group N.V.'s P/E ratio, and how does it compare with its own history? Pharming Group N.V.'s P/E is 43.8×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Pharming Group N.V. business getting better or worse? Pharming Group N.V.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Pharming Group N.V. earn on its capital? Pharming Group N.V. earned a ROE of 1% in FY25. That is up from a low of −5% in FY24. Its return on capital used (ROIC) is 11.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 0.8% net margin and 0.75× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 0.8% net margin × 0.75× asset turnover × 1.80× leverage (assets divided by equity) ≈ 1.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 15.8% − 4.5% = +11.3 percentage points. The 4.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 15.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 3.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Pharming Group N.V. have too much debt? Pharming Group N.V. has total debt of $113 M against shareholder equity of $270 M as of Jun 2026, so its debt is 0.42× its equity. Year by year, that ratio went from 0.84 in FY21 to 0.42 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Pharming Group N.V. shareholding pattern? 0.0% of Pharming Group N.V.'s tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 0.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Pharming Group N.V. from balance-sheet trouble? For Pharming Group N.V., the Z-score is 3.90. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.90 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Pharming Group N.V. rank in its industry? There is no score against its industry: Pharming Group N.V. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Pharming Group N.V. compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Pharming Group N.V. in size? Pharming Group N.V. is the 117th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: MeiraGTx Holdings plc, Prime Medicine, Inc. and Theravance Biopharma, Inc. Just below it: Aktis Oncology, Inc., Ardelyx, Inc. and Arbutus Biopharma Corporation. ### Biotechnology companies close in size

1. [MeiraGTx Holdings plc](https://www.sectoralpha.in/us/stocks/mgtx) $905 million
2. [Prime Medicine, Inc.](https://www.sectoralpha.in/us/stocks/prme) $884 million
3. [Theravance Biopharma, Inc.](https://www.sectoralpha.in/us/stocks/tbph) $884 million
4. Pharming Group N.V. $880 million
5. [Aktis Oncology, Inc.](https://www.sectoralpha.in/us/stocks/akts) $845 million
6. [Ardelyx, Inc.](https://www.sectoralpha.in/us/stocks/ardx) $827 million
7. [Arbutus Biopharma Corporation](https://www.sectoralpha.in/us/stocks/abus) $803 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Prime Medicine, Inc.](https://www.sectoralpha.in/us/stocks/prme) $884 million · Biotechnology
2. [Theravance Biopharma, Inc.](https://www.sectoralpha.in/us/stocks/tbph) $884 million · Biotechnology
3. Pharming Group N.V. $880 million
4. [Douglas Dynamics, Inc.](https://www.sectoralpha.in/us/stocks/plow) $880 million · Auto Parts
5. [JBG SMITH Properties](https://www.sectoralpha.in/us/stocks/jbgs) $880 million · REIT - Diversified

## What else do people ask about Pharming Group N.V.? ### What were Pharming Group N.V.'s latest quarterly results? Pharming Group N.V. reported revenue of $90.2 M and net profit of $1.6 M for the Jun 2026 quarter. Revenue fell 3.2% and profit fell 65.1% compared with a year earlier. Earnings per share were $0.00. The operating margin was 1.5%, 10.1 percentage points lower than a year earlier (as of 4 November 2026). ### What is Pharming Group N.V.'s market cap? Pharming Group N.V.'s market capitalisation is $880 M at a stock price of $12.46. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Pharming Group N.V. performing? Pharming Group N.V.'s share price has been falling for 5 weeks. In its latest quarter, revenue fell 3.2% and profit fell 65.1% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running (as of 4 November 2026). ### Will Pharming Group N.V.'s stock price go up? This page does not forecast Pharming Group N.V.'s stock price. What it shows instead: the stock price is $12.46, and it has been falling for 5 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Does Pharming Group N.V. have too much debt? Pharming Group N.V. has a moderate amount of debt: its debt is 0.39× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026). ### Where is Pharming Group N.V. in its business cycle? Pharming Group N.V.'s FY25 operating margin was 8.7%, against a 5-year range of −8.9% to 12.1%: the middle of its own range, neither a peak nor a low. The latest quarter was 1.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Pharming Group N.V. story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Pharming Group N.V. a stock worth studying right now? What the numbers show: Pharming Group N.V.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.